Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by BlaineBorgon Jul 15, 2021 11:40pm
296 Views
Post# 33557514

RE:RE:RE:What is the reason

RE:RE:RE:What is the reasonChristopher Moreau, the CEO is in bed with Kulwant Malhi. The #1 common shareholder and institutional investors of Algernon stock. He has gone to work for Kulwant Malhi at First Responder Technologies before it's complete meltdown. The CEO also chose to create a conflict of interest by appointing the BioPub owner (Dr. KSS) to the advisory board. In that capacity the CEO has held at least 1 private meeting with KSS's group of stock flippers. We also know for a fact Kulwant Malhi flips millions of shares of Algernon. How anyone can say go back to trusting someone who blatantly disrespects shareholders for his own personal gain and others given preferential treatment is not taking matters seriously. The CEO has shown us what he's willing to sacrifice for his group of investors He's willing to trash the reputation of a publicly traded company in broad daylight. Now he's acting surprised the stock has crashed to crazy lows by claiming the stock is trading like a covid stock. He's too delusional to realize he spent 90% of the company messaging on covid leading up to the failed topline data readout. The CEO is losing the company out from under us by his actions. He drove the pennyland bus over the cliff. He alone did it. Nobody else. There is no trust to be had. Only accountability. Show us the FDA meeting minutes. We don't believe you Christopher J. Moreau.
Flyer47 wrote: Agreed, he needs to relese the meeting minutes to show a minimum of good faith.
Otherwise we can not return to tusting him.


<< Previous
Bullboard Posts
Next >>